FZB NeuesLogo 2017 Deutsch

Die Lunge im Fokus
Die Lunge im Fokus
Die Lunge im Fokus
Die Lunge im Fokus
die-lunge-im-fokus-fzb.jpg
Focus on the lungs
We are the lung research center of the Leibniz Association.
Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).
Our Mission
die-lunge-im-fokus-fzb.jpg
Chronic lung diseases
The program area is dedicated to research into asthma, COPD and allergies, as these are among the most common chronic diseases and therefore cause an enormous burden for both patients and healthcare systems.
Priority Research Area
die-lunge-im-fokus-fzb.jpg
Infections
The Infections program area is dedicated to researching and combating bacterial infectious diseases of the lung with a focus on tuberculosis.
The aim is to improve the control and treatment of this disease.
To the program area
die-lunge-im-fokus-fzb.jpg
Science & Technology
This area combines overarching research units that are essential for research at the FZB and represent an important link between the subject areas.
Further Information
previous arrow
next arrow

News

  • calendar regular18.02.2025

    Novel antibiotic BTZ-043 also reaches tuberculosis bacteria hiding in dead lung tissue

    Every year, 10 million people contract tuberculosis (TB). Around 1.5 million patients succumb to the disease. The novel antibiotic BTZ-043 has shown good bactericidal activity in human clinical trials. DZIF scientists led by the University of Bayreuth and the FZB were able to show that BTZ-043 effectively penetrates TB lesions, accumulates there and can thus fight the Mtb bacteria even in hard-to-reach areas.

  • calendar regular18.02.2025

    Young scientist wins DZIF/DGI 2025 poster award

    At this annual joint congress of the German Center for Infection Research (DZIF) and the German Society for Infectious Diseases (DGI) in Munich, Dariusz Wölk, medical student at the University of Hamburg and doctoral candidate in the Clinical Infectious Diseases group at the Research Center Borstel, Leibniz Lung Center, has been awarded 500 € for the best poster.

  • calendar regular17.02.2025

    EndTB trial: Shorter and highly effective treatments for drug-resistant tuberculosis

    Treatment options for persons affected by drug-resistant tuberculosis are rapidly improving. While 2 years ago standard antibiotic therapy was still recommended for 18 months with then available medicines - leading to approximately 60% of individuals achieving treatment success - novel regimens for drug-resistant tuberculosis are shorter and more effective.

Events

  • Leibniz Research Alliance  INFECTIONS - Symposium  “Antimicrobial resistance: The silent pandemic”

    calendar regular10.+11. März 2025
    location dot solidISAS, Dortmund

  • Tuberkulose aktuell 2025

    calendar regular24. März 2025
    location dot solidBorstel

  • 37. Allergie-Kolloquium - „Update Allergologie“

    calendar regular10. Mai 2025
    location dot solidBorstel